Novartis AG (NVSEF)

OTCMKTS · Delayed Price · Currency is USD
107.55
0.00 (0.00%)
Mar 26, 2025, 4:00 PM EST
12.41%
Market Cap 212.41B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
Shares Out n/a
EPS (ttm) 5.87
PE Ratio 17.79
Forward PE n/a
Dividend 3.97 (3.41%)
Ex-Dividend Date Mar 11, 2025
Volume 650
Average Volume 84,345
Open 109.00
Previous Close 107.55
Day's Range 107.55 - 109.00
52-Week Range 90.24 - 123.55
Beta 0.49
RSI 45.11
Earnings Date Apr 29, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]

Sector Healthcare
Founded 1996
Employees 75,883
Stock Exchange OTCMKTS
Ticker Symbol NVSEF
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial Statements

News

FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE: NVS) Pluvicto for prostate cancer patients . The expanded indication, which approximately triples the number of pat...

16 hours ago - Benzinga

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now ...

19 hours ago - GlobeNewsWire

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

4 days ago - GlobeNewsWire

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE: NVS) oral Fabhalta (iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the uri...

7 days ago - Benzinga

Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G

Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G

8 days ago - Seeking Alpha

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C...

8 days ago - PRNewsWire

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

8 days ago - GlobeNewsWire

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders

Monte Rosa's MRT-6160 shows promising Phase 1 ... Full story available on Benzinga.com

8 days ago - Benzinga

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July

On Thursday, PTC Therapeutics, Inc. (NASDAQ: PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genom...

8 days ago - Benzinga

Novartis succeeds in trials for spinal muscular atrophy treatment in 2 to 18-year-olds

Novartis' OAV101 IT gene therapy shows promising results for spinal muscular atrophy patients aged 2-18, improving motor function in late-stage trials. Read more here.

9 days ago - Seeking Alpha

Novartis scraps use of diverse panels for hires in US

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surroundi...

9 days ago - Reuters

Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'

Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said...

12 days ago - Reuters

Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market

Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed compreh...

14 days ago - GlobeNewsWire

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ: CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer trea...

15 days ago - Benzinga

NFL signs Novartis as first pharmaceutical partner-source

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.

16 days ago - Reuters

Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy

BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initi...

16 days ago - GlobeNewsWire

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shareh...

21 days ago - GlobeNewsWire

10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil

The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d...

23 days ago - Seeking Alpha

Novartis not panicking over potential US pharmaceutical tariffs, chairman says

Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thur...

23 days ago - Reuters

Final Trade: NVS, XLU, GM

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

23 days ago - CNBC Television

Final Trade: NVS, XLU, GM

The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.

23 days ago - CNBC

Novartis AG (NVS) Showcases Promising Data at AAAAI and AAD Meetings

Novartis AG (NVS) Showcases Promising Data at AAAAI and AAD Meetings

4 weeks ago - GuruFocus

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III ...

4 weeks ago - PRNewsWire